Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2011 to YTD 2017 11
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
ILiAD Biotech Raises USD0.5 Million in Venture Financing 15
ILiAD Biotech Raises USD1 Million in Venture Financing 16
ILiAD Biotech Raises USD0.6 Million in Venture Financing 17
Partnerships 18
Genisphere Enters into Agreement with Inserm 18
TxCell Enters into R&D Agreement with Inserm Transfert 19
Evotec Enters into Research Agreement with Inserm Transfert 20
Pierre Fabre Medicament Partners with Inserm Transfert 21
AstraZeneca Enters into Research Agreement with Inserm 22
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 23
Mifcare Enters into Agreement with Inserm 24
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 25
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 27
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 29
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 30
Areva Enters into Research Agreement with French National Institute of Health and Medical Research 31
Licensing Agreements 32
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 32
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 33
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 34
Brainvectis Enters into Licensing Agreement with INSERM 35
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 36
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 37
Inserm Transfert Enters into Licensing Agreement with HalioDx 38
IntegraGen Enters into Licensing Agreement with Inserm 39
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 40
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 41
La Jolla Pharma Enters Into Licensing Agreement With Inserm To Develop Hepcidin Agonists 42
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 43
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 44
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 45
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 46
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 48
ViThera Pharma Enters into Licensing Agreement with French National Institute of Health and Medical Research and National Institute of Agricultural Research 50
French National Institute of Health and Medical Research – Key Competitors 51
French National Institute of Health and Medical Research – Key Employees 52
French National Institute of Health and Medical Research – Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Affiliate 53
Recent Developments 54
Product News 54
07/19/2016: An Antibody-based Drug for Multiple Sclerosis 54
Apr 08, 2016: An effective drug for myoclonus-dystonia, a rare disease of the nervous system 55
Feb 29, 2016: Peptimimesis: New Biotech Startup Developing Next Generation Therapeutic Peptides In Immuno -Oncology, Oncology And Immune Diseases 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Key Facts 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
French National Institute of Health and Medical Research, Deals By Therapy Area, 2011 to YTD 2017 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2011 to YTD 2017 11
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
ILiAD Biotech Raises USD0.5 Million in Venture Financing 15
ILiAD Biotech Raises USD1 Million in Venture Financing 16
ILiAD Biotech Raises USD0.6 Million in Venture Financing 17
Genisphere Enters into Agreement with Inserm 18
TxCell Enters into R&D Agreement with Inserm Transfert 19
Evotec Enters into Research Agreement with Inserm Transfert 20
Pierre Fabre Medicament Partners with Inserm Transfert 21
AstraZeneca Enters into Research Agreement with Inserm 22
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 23
Mifcare Enters into Agreement with Inserm 24
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 25
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 27
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 29
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 30
Areva Enters into Research Agreement with French National Institute of Health and Medical Research 31
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 32
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 33
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 34
Brainvectis Enters into Licensing Agreement with INSERM 35
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 36
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 37
Inserm Transfert Enters into Licensing Agreement with HalioDx 38
IntegraGen Enters into Licensing Agreement with Inserm 39
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 40
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 41
La Jolla Pharma Enters Into Licensing Agreement With Inserm To Develop Hepcidin Agonists 42
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 43
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 44
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 45
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 46
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 48
ViThera Pharma Enters into Licensing Agreement with French National Institute of Health and Medical Research and National Institute of Agricultural Research 50
French National Institute of Health and Medical Research, Key Competitors 51
French National Institute of Health and Medical Research, Key Employees 52
French National Institute of Health and Medical Research, Subsidiaries 53
French National Institute of Health and Medical Research, Affiliate 53